A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study to Compare the Pharmacokinetics of CJ-30039 and Lipidil Supra and to Investigate Food-effect on Pharmacokinetics of CJ-30039
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2017
At a glance
- Drugs CJ 30039 (Primary) ; Fenofibrate
- Indications Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
- Focus Pharmacokinetics
- Sponsors CJ Corporation
- 01 Aug 2012 Actual patient number (48) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.